25 January 2022
Top hires for VC & PE portfolio companies Q4-2021
Search Highlights
Recent top global hires for Venture Capital and Private Equity backed companies, covering a broad range of disciplines and sectors across Life Sciences, Health, and Tech.
This quarter’s successful placements include:
| Function | Focus area | Location |
|---|---|---|
| CEO | RNA epigenetics | Belgium |
| CEO | Novel small molecules | US |
| President US | Immuno-oncology | China |
| Chief Scientific Officer | Oncology | China |
| Chief Technology Officer | Cardiovascular devices | France |
| Chief Medical Officer | Oncology and rare diseases | UK |
| Chief Financial Officer | Precision cancer therapeutics | US |
| Chief Commercial Officer | Digital pathology | France |
| Regional Chief Financial Officer | Veterinary services | Nordics |
| SVP Biology | Protein degradation therapeutics | UK |
| SVP Chemistry | RNA activation-based therapies | UK |
| EVP Commercial | Clinical research services | Germany |
| VP Immunology | Cell therapy | Switzerland |
| Head of Project & Portfolio Management | mRNA immunotherapies | UK |
| 2x Board Directors | Autoimmunology disorders | Denmark |
| Associate | Life science venture capital | Netherlands |
Newly opened projects include:
| Function | Focus area | Location |
|---|---|---|
| Group CEO | Outpatient services | Switzerland |
| CEO | A.I. for drug discovery | US |
| CEO | Synthetic biology technologies | UK |
| CEO | Surgical robotics | Switzerland |
| Chief Financial Officer | RNA-based therapeutics | Germany |
| Chief Medical Officer | Oncology | US |
| Chief Commercial Officer | Rapid diagnostics | Belgium |
| Chief Scientific Officer | Protein degrading therapeutics | US |
| SVP Clinical Development | Digital therapeutics | Nordics |
| Head of Sales, Americas | A.I-enabled diagnostics | Nordics |
| VP RA/QA | CNS diseases | Singapore |
| VP, Molecular Pharmacology | RNA interference | US |
| Chair | Cardiac diseases | Germany |
| Investment Manager | Medtech growth investor | Sweden |